<DOC>
	<DOCNO>NCT00056238</DOCNO>
	<brief_summary>The main objective study evaluate safety , tolerability pharmacokinetics Cerebril™ Cerebral Amyloid Angiopathy ( CAA ) patient lobar cerebral hemorrhage .</brief_summary>
	<brief_title>Cerebril™ Patients With Lobar Hemorrhage Related Cerebral Amyloid Angiopathy</brief_title>
	<detailed_description>Hemorrhagic Stroke due CAA represent approximately 7 % stroke . The current phase II clinical study investigate safety , tolerability , pharmacokinetic pharmacodynamic profile drug candidate patient suffer lobar hemorrhage . The initial phase study also aim determine optimal dosing regimen subsequent drug candidate efficacy trial . The trial also evaluate appearance new cerebral hemorrhage gradient-echo MRI scan , amyloid ß ( Aß ) protein level plasma cerebrospinal fluid neurological cognitive function .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Cerebral Amyloid Angiopathy</mesh_term>
	<mesh_term>Cerebral Amyloid Angiopathy , Familial</mesh_term>
	<criteria>Inclusion Criteria Patients must 55 year age old . Males female . Females must nonchildbearing potential ( i.e . surgically sterilize least one year postmenopausal ) . Diagnosis possible probable CAA base Boston Criteria Diagnosis CAARelated Hemorrhage . Nonfatal lobar hemorrhage ( defined hemorrhage cerebral cortex underlie white matter spar basal ganglion thalamus ) within previous five year diagnose CT MRI scan . Patient intent donate blood 4 week completion study . Signed informed consent . Exclusion Criteria Other establish cause hemorrhage time index hemorrhage event . Exclusion cause include excessive anticoagulation ( INR &gt; 4.0 ) , associate head trauma ischemic stroke , CNS tumor , vascular malformation , vasculitis , blood dyscrasia . Patient clinically significant uncontrolled cardiovascular , renal , hepatic , pulmonary , gastrointestinal , endocrine , metabolic , ophthalmologic , hematological condition significant medical disease . Presence condition could interfere interpretation study result compromise patient safety . Debilitated neurological state know disease likely result early death . Disability characterize modify Rankin score ≥ 4 . ALT , ALP , AST total bilirubin ≥ 1.5 upper limit normal range . Contraindications MRI scan ( e.g . cranial metallic implant , cardiac pacemaker , severe claustrophobia ) . Allergy and/or hypersensitivity analgesic agent use lumbar puncture ( patient undergo lumbar puncture ) . Allergy and/or hypersensitivity component study medication . Use investigational drug within 30 day prior Screening visit . Use warfarin warfarin contain compound heparin heparin contain compound within 7 day prior Baseline ( Week 0 ) visit . Diagnosis cystatin C amyloid angiopathy . Active alcohol and/or drug abuse . Inability provide legal consent</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>Neurologic Diseases ( General )</keyword>
	<keyword>Hemorrhagic Stroke</keyword>
	<keyword>Cerebral Amyloid Angiopathy</keyword>
	<keyword>Cerebrovascular Accident</keyword>
</DOC>